Ecromeximab
Monoclonal antibody
NY (what is this?) (verify) Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma.[1][2]
The drug was developed by Kyowa Hakko Kogyo Co., Ltd. As of December 2015 development had been discontinued.[3]
References
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Ecromeximab, American Medical Association.
- ^ Clinical trial number NCT00679289 for "Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Cutaneous Melanoma" at ClinicalTrials.gov
- ^ Adis insight: Ecromeximab
- v
- t
- e
Monoclonal antibodies for tumors
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e